Geneva, Switzerland - The Wyss Center for Bio and Neuroengineering, a non-profit organization dedicated to accelerating discoveries in neuroscience to improve patient lives, has joined BioAlps, the life sciences cluster for Western Switzerland.
“We are honored that the Wyss Center for Bio and Neuroengineering has agreed to join BioAlps. This leading research center is a pioneer in neuroscience and its innovations in neurobiology and neurotechnology help create and inspire the therapies of tomorrow. Its contribution to the life sciences ecosystem in Western Switzerland is absolutely necessary and valuable”, says Magali Bischof, Secretary General of BioAlps.
BioAlps has established a dynamic biotech, medtech and digital health network in Western Switzerland. Comprising research centers, universities, hospitals, startup companies and multinationals. The BioAlps association powers knowledge exchange, supports the translation of technologies from research to industrial settings and, through its networking activities, provides access to local and international partners.
“With the beating heart of the Wyss Center based in Western Switzerland, it is only natural for us to foster and support our local ecosystem in which BioAlps plays a very important role. At the same time, BioAlps is much more than a local Swiss network. As we strive to address global neuroscience challenges, BioAlps also offers fantastic opportunities to reach international audiences”, says George Kouvas, MBA, Chief Technology Officer at the Wyss Center.
The Wyss Center advances understanding of the brain and drives development of transformative bio and neurotechnologies. The Center’s activities address indications such as epilepsy, Alzheimer’s disease and locked-in syndrome as a result of ALS (amyotrophic lateral sclerosis). The Wyss Center team has wide ranging expertise in neurobiology, advanced imaging, technology development and regulatory affairs. The Center works closely with clinical partners and patients to develop and implement novel diagnostics and therapies.
Symposium: As the BCI community shifts its focus to clinical studies for patient benefit, join us to hear from researchers and companies working together at the forefront of BCI development discussing paths to translation and BCI home-use.
Wyss Center’s ABILITY system, designed to improve quality of life and independence for people with severe paralysis, demonstrates safety and efficacy in pre-clinical trials.
New Wyss Center whitepaper reveals first neural signals recorded by the ABILITY brain-computer interface system and the next steps to human clinical trials to restore communication and independence for people with severe paralysis.
We welcome new opportunities to exchange ideas and to explore collaborations
Collaborate with usWe are searching for innovative and driven people to make a difference
Join our teamWe welcome feedback on our projects
Provide feedback
